[go: up one dir, main page]

UA94246C2 - Производные индазола, которые ингибируют рецептор trpv1 - Google Patents

Производные индазола, которые ингибируют рецептор trpv1

Info

Publication number
UA94246C2
UA94246C2 UAA200807267A UAA200807267A UA94246C2 UA 94246 C2 UA94246 C2 UA 94246C2 UA A200807267 A UAA200807267 A UA A200807267A UA A200807267 A UAA200807267 A UA A200807267A UA 94246 C2 UA94246 C2 UA 94246C2
Authority
UA
Ukraine
Prior art keywords
indazole derivatives
trpvl receptor
inhibit
inhibit trpvl
receptor
Prior art date
Application number
UAA200807267A
Other languages
English (en)
Ukrainian (uk)
Inventor
Артур Р. Гомтсян
Эрол К. Бейберт
Джон Р. Кениг
Кеннан К. МАРШ
мл. Шмидт Роберт Г.
Чих-Хун Ли
Вейли Ванг
Джером Ф. Даанен
Брайан С. Браун
Original Assignee
Эбботт Леборетриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Леборетриз filed Critical Эбботт Леборетриз
Publication of UA94246C2 publication Critical patent/UA94246C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Соединения формулы (I),где A, R, Rи Rимеют значения, указанные в описании,которые пригодны как терапевтические соединения, в частности, для лечения нарушений или состояний, связанных с воспалением, болью, повышенной активностью мочевого пузыря, недержанием мочи и других нарушений, вызванных или обостренных TRPV1.
UAA200807267A 2005-10-28 2006-10-27 Производные индазола, которые ингибируют рецептор trpv1 UA94246C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73099105P 2005-10-28 2005-10-28

Publications (1)

Publication Number Publication Date
UA94246C2 true UA94246C2 (ru) 2011-04-26

Family

ID=37668287

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200807267A UA94246C2 (ru) 2005-10-28 2006-10-27 Производные индазола, которые ингибируют рецептор trpv1

Country Status (15)

Country Link
US (2) US8232309B2 (ru)
EP (1) EP1957464A1 (ru)
JP (1) JP2009513659A (ru)
KR (1) KR20080067361A (ru)
CN (2) CN102516176A (ru)
AU (1) AU2006306146A1 (ru)
BR (1) BRPI0617884A2 (ru)
CA (1) CA2626593A1 (ru)
IL (1) IL190899A0 (ru)
NZ (1) NZ567358A (ru)
RU (1) RU2008121205A (ru)
TW (1) TW200819441A (ru)
UA (1) UA94246C2 (ru)
WO (1) WO2007050732A1 (ru)
ZA (1) ZA200803674B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
WO2006065484A2 (en) 2004-11-24 2006-06-22 Abbott Laboratories Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
EP1902084A2 (en) 2005-06-01 2008-03-26 Yissum Research Development Company, of The Hebrew University of Jerusalem Biodegradable polymers having a pre-determined chirality
JP2009534399A (ja) 2006-04-18 2009-09-24 アボット・ラボラトリーズ バニロイド受容体サブタイプ１型（ｖｒ１）の拮抗薬およびその使用
EP2238105B1 (en) 2008-01-28 2014-04-16 Amorepacific Corporation Novel compounds as vanilloid receptor antagonists
KR101621444B1 (ko) 2008-07-02 2016-05-19 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물
US8609692B2 (en) 2008-10-17 2013-12-17 Abbvie Inc. TRPV1 antagonists
WO2010045401A1 (en) * 2008-10-17 2010-04-22 Abbott Laboratories Trpv1 antagonists
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
AU2010289143A1 (en) 2009-08-24 2012-02-16 Ascepion Pharmaceuticals, Inc. 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
DE112010005848B4 (de) 2010-09-06 2016-03-10 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences Amidverbindungen
CA2826648C (en) * 2011-02-18 2019-06-04 Endo Pharmaceuticals Inc. Aminoindane compounds and use thereof in treating pain
AR085530A1 (es) 2011-03-25 2013-10-09 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
MX2014013489A (es) * 2012-05-09 2015-02-12 Bayer Cropscience Ag 5-halogenopirazolindanil carboxamidas.
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
JP2016512831A (ja) 2013-03-15 2016-05-09 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたパルボシクリブ
WO2014193696A2 (en) * 2013-05-28 2014-12-04 Transtech Pharma, Llc Benzimidazole carboxylic acid derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
US9783527B2 (en) * 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
US20170008905A1 (en) 2015-07-06 2017-01-12 Gilead Sciences, Inc. Cot modulators and methods of use thereof
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
TWI778562B (zh) 2020-04-02 2022-09-21 美商基利科學股份有限公司 製備cot抑制劑化合物的方法
CN113292485B (zh) * 2021-06-08 2023-10-27 河南大学 苄基哌嗪脲类trpv1拮抗和mor激动双靶点药物及制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
SI1658269T1 (sl) * 2003-06-12 2009-04-30 Abbott Lab Kondenzirane spojine za inhibicijo vaniloidnega receptorja podvrste (VR1) receptorja
US7375126B2 (en) * 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2006065484A2 (en) 2004-11-24 2006-06-22 Abbott Laboratories Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof

Also Published As

Publication number Publication date
BRPI0617884A2 (pt) 2011-08-09
JP2009513659A (ja) 2009-04-02
RU2008121205A (ru) 2009-12-10
AU2006306146A1 (en) 2007-05-03
ZA200803674B (en) 2009-11-25
IL190899A0 (en) 2008-11-03
CN101365684A (zh) 2009-02-11
CA2626593A1 (en) 2007-05-03
CN102516176A (zh) 2012-06-27
US8232309B2 (en) 2012-07-31
NZ567358A (en) 2011-10-28
WO2007050732A1 (en) 2007-05-03
US20070099954A1 (en) 2007-05-03
EP1957464A1 (en) 2008-08-20
US20120277190A1 (en) 2012-11-01
TW200819441A (en) 2008-05-01
KR20080067361A (ko) 2008-07-18

Similar Documents

Publication Publication Date Title
UA94246C2 (ru) Производные индазола, которые ингибируют рецептор trpv1
NL301145I1 (ru)
WO2007145835A3 (en) Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2010038086A3 (en) P38 map kinase inhibitors
MY142496A (en) 2,4-diamino-pyrimidines as aurora inhibitors
TW200607513A (en) Certain chemical entities, compositions, and methods
MX2009001327A (es) Compuestos de indol.
WO2007024717A3 (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
MXPA04002983A (es) Derivados de quinuclidina, procedimientos para prepararlos y sus usos como inhibidores del receptor muscar??nico m2 y/o m3.
TW200600506A (en) Substituted morpholine compounds for the treatment of central nervous system disorders
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
WO2008062276A3 (en) Acetylene derivatives as stearoyl coa desaturase inhibitors
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
WO2007120333A3 (en) Tetracyclic kinase inhibitors
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
MX2010007392A (es) Antagonistas de trpa1.
WO2010033543A3 (en) Substituted benzamides as cannabinoid receptor ligands
IL195217A0 (en) Protein kinase inhibitors and uses thereof
MX2010007391A (es) Antagonistas de trpa1.
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
WO2007109251A3 (en) Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
MX2008001428A (es) Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.